New biologics for food allergy

Jackson P Schuetz,Brent Anderson,Sayantani B Sindher,Jackson P. Schuetz,Sayantani B. Sindher
DOI: https://doi.org/10.1097/aci.0000000000000981
2024-03-30
Current Opinion in Allergy and Clinical Immunology
Abstract:This review aims to explore role of emerging biologics, including ligelizumab, UB-221, dupilumab, and antialarmins, in food allergy management. With a focus on recent developments, we evaluate their promise in mitigating adverse events during oral immunotherapy (OIT), reducing allergic reactions, and addressing the limitations of current therapeutic options.
immunology,allergy
What problem does this paper attempt to address?